tbuckley/cabot-search huggingface dataset:
Executive Summary: 2020 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations
Authors: Jerry P. Nolan, Ian Maconochie, Jasmeet Soar, Theresa M. Olasveengen, Robert Greif, Myra H. Wyckoff, Eunice M. Singletary, Richard Aickin, Katherine M. Berg, Mary E. Mancini, Farhan Bhanji, Jonathan Wyllie, David Zideman, Robert W. Neumar, Gavin D. Perkins, Maaret Castrén, Peter T. Morley, William H. Montgomery, Vinay M. Nadkarni, John E. Billi, Raina M. Merchant, Allan de Caen, Raffo Escalante-Kanashiro, David Kloeck, Tzong-Luen Wang, Mary Fran Hazinski
Journal: Circulation (2020)
DO THE CEREALS HAVE UNLIKE VALUES IN NUTRITION?
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
68Ga-FAPI PET/CT Findings in a Rare Presacral Myxopapillary Ependymoma
Authors: Chongjiao Li, Bing Wen, Yueli Tian, Jie Chen, Yong He
Journal: Clinical Nuclear Medicine (2022)

Abstract Myxopapillary ependymoma is a rare tumor. Most of them occur exclusively in the conus medullaris, cauda equina, or filum terminale. Here, we present the 68 Ga-FAPI PET/CT findings in a 37-year-old woman with presacral myxopapillary ependymoma.
在 COVID‐19 疫情期间观察到的大多数冻疮与 COVID‐19 感染无关
Journal: British Journal of Dermatology (2020)

COVID‐19 是一种由冠状病毒 SARS‐CoV‐2 引起的传染病。首先在中国武汉报告了第一例病例，然后感染随后传播到世界其他地方。除了感染的主要症状（发热、咳嗽和呼吸困难）外，还报告了不同类型的皮肤表现（体征）。最常见的类型是脚趾呈红色/紫色，类似于冻疮——这是一种皮肤疾病，通常与暴露在寒冷的温度下有关。这些与 COVID‐19 相关的“肢端病变”主要见于青少年和青年人，临床上被描述为“假性冻疮”。
P441 – P678
Authors: B Zimmer, S Mirrett, L Reller, M Weinstein, J Hindler, R Carey, S Mcallister, D Bruckner, J Johnston, K Sei, T.-D Huang, C Laurent, J Gigi, A Simon, M Armengol, J Calvo, L Martinez, C Salas, J Herna ´ndez, B Ruiz, M Conejo, A Pascual, L Martinez-Martinez, N Stone, C O'hara, P Williams, J Mcgowan, F Tenover
Journal: Clinical Microbiology and Infection (2006)
Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation: A retrospective analysis.
Authors: Kyunghye Bang, Changhoon Yoo, Min-Hee Ryu, Sook Ryun Park, Hyung-Don Kim, Baek-Yeol Ryoo
Journal: Journal of Clinical Oncology (2022)

410 Background: Lenvatinib is approved for use in patients with metastatic or recurrent hepatocellular carcinoma (HCC); however, its clinical outcomes in patients experiencing HCC recurrence after liver transplantation (LT), remain unclear. Further, despite of immunotherapeutic advances (atezolizumab plus bevacizumab, pembrolizumab, and nivolumab) in the management of advanced HCC, patients with prior LT are not benefited because of the risk of allograft rejection, and they are also excluded in the most prospective clinical trials for novel agents. Thus, we investigated the efficacy and safety of lenvatinib treatment in patients with recurrent HCC after LT. Methods: This single center, retrospective study included 22 patients with recurrent HCC after LT who received lenvatinib at the Asan Medical Center, South Korea, between November 2019 and March 2021. Lenvatinib was given 12mg/day for bodyweight ≥ 60 kg or 8 mg/day for bodyweight &lt; 60 kg. Response and adverse events (AEs) were graded according to RECIST v1.1 and NCI CTCAE v5.0. Results: The median age was 58 years (range, 20-69) and 95.5% (n = 21) were male. Most common etiology of HCC was hepatitis B (n = 18, 81.8%). The median time to recurrence after LT was 6.6 months (95% CI, 4.2-9.1 months). Prior to systemic therapy, transarterial embolization (TACE) (n = 12, 54.5%) was the most commonly used therapy for recurred HCC after LT. At the time of lenvatinib initiation, 95.5% (n = 21) of the patients were Child-Pugh A with 15 (68.2%) and 7 (31.8%) patients classified as ALBI grades 1 and 2, respectively. All patients were at BCLC stage C and lenvatinib was administered as first-line (n = 19) and second-line (n = 3) therapy. The objective response rate (ORR) was 13.6%. With a median follow-up duration of 5.2 months (range, 1.7-14.5 months), the median progression-free survival (PFS) was 6.6 months (95% CI: 3.6-9.5 months) and overall survival (OS) was 14.5 months (95% CI: not assessable). The 6-month PFS and OS rates were 59.8% and 88.8%, respectively. Patients with ALBI grade 2 showed significantly poorer OS [11.1 months (95% CI: not assessable)] compared to patients with ALBI grade 1 [14.5 months (95% CI: not assessable)] ( p= 0.011). AEs were hypertension (n = 8, 36.4%), thrombocytopenia (n = 7, 31.8%), and fatigue (n = 6, 27.3%). Conclusions: Lenvatinib was effective and showed manageable toxicities in patients with recurrent HCC after LT. These outcomes are comparable to those from the pivotal REFLECT trial where patients with LT were excluded. Better baseline liver function (ALBI grade 1) at lenvatinib initiation correlated with better survival outcomes.
Abstract 249: Chronic Neuregulin-1β Treatment Mitigates the Progression of Post-myocardial Infarction Heart Failure in the Setting of Type 1 Diabetes Mellitus
Authors: Manisha Gupte, Hind Lal, Firdos Ahmad, Lin Zhong, Douglas B Sawyer, Michael F Hill
Journal: Circulation Research (2017)

Aim: Neuregulin-1β (NRG-1β), a growth factor critical for cardiac development as well as maintenance of heart function after injury has been shown to significantly improve heart function in preclinical rodent models. Importantly, number of studies are ongoing to test the efficacy of NRG-1β as a treatment for patients with chronic heart failure. However, the efficacy of recombinant NRG-1β in a typ1 diabetic model of heart failure due to myocardial infarction (MI) has not been investigated. The aim of the present study was to determine the efficacy of exogenous NRG-1β to improve residual cardiac function after MI in type1 diabetic rats. Methods and Results: Sprague Dawley rats were induced type 1 diabetes by a single injection of streptozotocin (STZ) (65 mg/kg). Two weeks after induction of type 1 diabetes, rats underwent left coronary artery ligation to induce MI. STZ-diabetic rats were treated with saline or NRG-1β (100 ug/kg) twice a week for 7 weeks, starting two weeks prior to experimental MI. Residual left ventricular (LV) function was significantly greater in the NRG-1β-treated STZ-diabetic MI group compared to the vehicle-treated STZ-diabetic MI group 5 weeks after MI as assessed by high-resolution echocardiography. Furthermore, NRG-1β treatment in STZ-diabetic MI rats reduced myocardial fibrosis and apoptosis as well as decreased gene expression of key oxidant-producing enzymes. Conclusion: This study demonstrates that augmentation of NRG-1β signaling in STZ-diabetic post-MI rats via therapy with exogenous recombinant NRG-1β will alleviate subsequent HF through improvements in residual LV function via protection against adverse remodeling and apoptosis.
Book Review Training and Efficiency . By E. Jokl, E. H. Cluver, C. Goedvolk and T. W. De Jongh. 4°, boards, 188 pp., with 28 illustrations and 18 plates. Johannesburg, South Africa: The South African Institute for Medical Research, 1941. 10s. 6d.
Journal: New England Journal of Medicine (1942)
Biomimetic Scaffolds Modulate the Posttraumatic Inflammatory Response in Articular Cartilage Contributing to Enhanced Neoformation of Cartilaginous Tissue In Vivo (Adv. Healthcare Mater. 1/2022)
Authors: Guillermo Bauza‐Mayol, Marcos Quintela, Ava Brozovich, Michael Hopson, Shazad Shaikh, Fernando Cabrera, Aaron Shi, Federica Banche Niclot, Francesca Paradiso, Emman Combellack, Tom Jovic, Paul Rees, Ennio Tasciotti, Lewis W. Francis, Patrick Mcculloch, Francesca Taraballi
Journal: Advanced Healthcare Materials (2022)

Cartilage Repair In article number 2101127 by Lewis W. Francis, Francesca Taraballi, and co-workers, a biomimetic immune tuning scaffold is implanted in a full-thickness chondral defect in rabbits. The early inflammatory infiltrates changed in the treated animals resulting in a better cartilage homeostasis at longer timepoints. This work represents the first approach of tuning the inflammatory reaction with a bulk material to achieve a better regeneration in cartilage.
Patients with three or more vessel disease treated with percutaneous interventions achieved similar safety long term outcome to those treated with conventional coronary bypass surgery: One year follow-up results from the ERAC II study Alfredo E. Rodriguez, Maximo Rodriguez Alemparte, Victor Bernardi, Julio Baldi, Jose Navia, Alejandro Delacasa, Daniel Vogel, Carlos Fernandez Pereira, Igor F. Palacios, William O'Neill. Otamendi Hospital, Buenos Aires, Argentina, William Beaumont Hospital, Royal …
Journal: Journal of the American College of Cardiology (2001)
TCT-845 Clinical Outcome Of Patients With Paradoxical Low-Flow, Low-Gradient Aortic Stenosis After Transcatheter Aortic Valve Implantation
Authors: Jury Schewel, Dimitry Schewel, Christian Frerker, Thomas Thielsen, Felix Meinke, Felix Kreidel, Karl-Heinz Kuck, Ulrich Schäfer
Journal: Journal of the American College of Cardiology (2012)
Beliefs Around Hypoglycemia and Their Impacts on Hypoglycemia Outcomes in Individuals with Type 1 Diabetes and High Risks for Hypoglycemia Despite Using Advanced Diabetes Technologies
Authors: Yu Kuei Lin, Caroline R. Richardson, Iulia Dobrin, Melissa J. DeJonckheere, Kara Mizokami-Stout, Michael D. Fetters, James E. Aikens, Simon J. Fisher, Wen Ye, Rodica Pop-Busui
Journal: Diabetes Care (2022)

OBJECTIVE This study aimed to 1) identify the frequency of severe and level 2 hypoglycemia presenting in individuals with type 1 diabetes using continuous glucose monitoring systems (CGMs), including those with concomitant closed-loop insulin pumps, in a clinical practice setting and 2) evaluate the impact of beliefs around hypoglycemia in the development of severe and level 2 hypoglycemia in this population. RESEARCH DESIGN AND METHODS A cross-sectional survey study in adults with type 1 diabetes using CGMs &amp;gt;6 months was conducted at a large tertiary academic center. Participant demographics, 6-month severe hypoglycemia history, hypoglycemia beliefs (with the Attitude to Awareness of Hypoglycemia questionnaire), and 4-week CGM glucose data were collected. Statistical analysis was performed to assess the presentation of severe and level 2 hypoglycemia and identify associated risk factors. RESULTS A total of 289 participants were recruited (including 257 participants with CGM data within the last 3 months). Of these, 25.6% experienced at least one severe hypoglycemic episode in the last 6 months, and 13.6% presented with ≥1% of time in level 2 hypoglycemia on CGMs. Reporting beliefs about prioritizing hyperglycemia avoidance was associated with severe hypoglycemia development (P &amp;lt; 0.001), while having beliefs of minimal concerns for hypoglycemia was associated with spending ≥1% of time in level 2 hypoglycemia (P = 0.038). CONCLUSIONS Despite the use of advanced diabetes technologies, severe and level 2 hypoglycemia continues to occur in individuals with type 1 diabetes and high hypoglycemia risks. Human factors, including beliefs around hypoglycemia, may continue to impact the effectiveness of glucose self-management.
Global Guidelines in Dermatology Mapping Project (<scp>GUIDEMAP</scp>), a systematic review of atopic dermatitis clinical practice guidelines: are they clear, unbiased, trustworthy and evidence based (<scp>CUTE</scp>)?*
Authors: Bernd W.M. Arents, Esther J. van Zuuren, Sofieke Vermeulen, Jan W. Schoones, Zbys Fedorowicz
Journal: British Journal of Dermatology (2022)

BackgroundClinical practice guidelines (CPGs) are essential in delivering optimum healthcare, such as for atopic dermatitis (AD), a highly prevalent skin disease. Although many CPGs are available for AD, their quality has not been critically appraised.
Gated myocardial perfusion SPECT has incremental value for predicting cardiac death in diabetic patients Sean W. Hayes, Enrique F. Schisterman, Howard C. Lewin, Xingping Kang, Ishac Cohen, Raluca D. Agafitei, John D. Friedman, Guido Germano, Daniel S. Berman. Cedars-Sinai Medical Center, Los Angeles, CA
Journal: Journal of the American College of Cardiology (2001)
The big disease with a little name
Authors: Talha Burki
Journal: The Lancet Infectious Diseases (2020)

The first episode of The big disease with a little name aired on BBC Radio 4 in early June, just as the UK was starting to ease its lockdown. The 12-part documentary series traces the history of HIV/AIDS. Listening to it in the era of COVID-19, one is struck by how much separates the two pandemics. HIV and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), needless to say, are entirely distinct. Mortality rates, routes of transmission, and disease course have little in common. Well under a year since SARS-CoV-2 was first detected, there are nine vaccine candidates in phase 3 trials, with several more in the pipeline.
Visual Field Loss Impacts Vision-Specific Quality of Life by Race and Ethnicity
Authors: Dominic J. Grisafe, Roberta McKean-Cowdin, Bruce S. Burkemper, Benjamin Y. Xu, Mina Torres, Rohit Varma, Xuejuan Jiang, Grace Richter, Farzana Choudhury, Tengiz Adamashvili, Carlos Lastra, Elizabeth Corona, YuPing Wang, Jacqueline Douglass, Jaimie Barrera, Judith Linton, Kisha Milo
Journal: Ophthalmology (2022)
Questions and Answers
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Risks of intrauterine contraceptive devices
Journal: BMJ (1984)

but no obstructing lesion or other abnormality were found.He had an uneventful recovery.Acute pseudo-obstruction of the large bowel is a recognised, potentially fatal, clinical syndrome.'The mechanism is unknown, but the condition may be associated with serious pathology inside or outside the abdomen.'-3Our experience suggests that pulmonary thromboembolism may lead to this condition.1 Addison NV.Pseudo-obstruction of the large bowel.
Contrast enhanced real-time 3D stress echocardiography improves endocardial delineation and reduces scanning time: Comparison with unenhanced 3D and conventional 2D stress echocardiography Andreas Franke, Christian H. P. Jansen, Laurent Visser, Rainer Hoffmann, Harald P. Kuehl, Peter Hanrath. Medizinische Klinik I, University Hospital, Aachen, Germany
Journal: Journal of the American College of Cardiology (2001)
Healthcare use in 700 000 children and adolescents for six months after covid-19: before and after register based cohort study
Authors: Karin Magnusson, Katrine Damgaard Skyrud, Pål Suren, Margrethe Greve-Isdahl, Ketil Størdal, Doris Tove Kristoffersen, Kjetil Telle
Journal: BMJ (2022)

Abstract Objectives To explore whether and for how long use of healthcare services is increased among children and adolescents after covid-19. Design Before and after register based study. Setting General population of Norway. Participants Norwegians aged 1-19 years (n=706 885) who were tested for SARS-CoV-2 from 1 August 2020 to 1 February 2021 (n=10 279 positive, n=275 859 negative) or not tested (n=420 747) and were not admitted to hospital, by age groups 1-5, 6-15, and 16-19 years. Main outcome measures Monthly percentages of all cause and cause specific healthcare use in primary care (general practitioner, emergency ward) and specialist care (outpatient, inpatient) from six months before to about six months after the week of being tested for SARS-CoV-2, using a difference-in-differences approach. Results A substantial short term relative increase in primary care use was observed for participants during the first month after a positive SARS-CoV-2 test result compared with those who tested negative (age 1-5 years: 339%, 95% confidence interval 308% to 369%; 6-15 years: 471%, 450% to 491%; 16-19 years: 401%, 380% to 422%). Use of primary care for the younger age groups was still increased at two months (1-5 years: 22%, 4% to 40%; 6-15 years: 14%, 2% to 26%) and three months (1-5 years: 26%, 7% to 46%, 6-15 years: 15%, 3% to 28%), but not for the oldest group (16-19 years: 11%, −2% to 24% and 6%, −7% to 19%, respectively). Children aged 1-5 years who tested positive also showed a minor long term (≤6 months) relative increase in primary care use (13%, −0% to 26%) that was not observed for the older age groups, compared with same aged children who tested negative. Results were similar yet the age differences less pronounced compared with untested controls. For all age groups, the increase in primary care visits was due to respiratory and general or unspecified conditions. No increased use of specialist care was observed. Conclusion Covid-19 among children and adolescents was found to have limited impact on healthcare services in Norway. Preschool aged children might take longer to recover (3-6 months) than primary or secondary school students (1-3 months), usually because of respiratory conditions.
Clinical Lectures on Neurasthenia, by Thomas D. Savill, M.D., London, Physician to the West End Hospital for Diseases of the Nervous System.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Efficacy of external cardioversion of atrial fibrillation in aged patients: Immediate and long-term results Stefano Fumagalli, Lorenzo Boncinelli, Ernesta Bondi, Veronica Caleri, Silvia Gatto, Giorgio Baldereschi, Paolo Valoti, Mauro Di Bari, Guilio Masotti, Niccolo' Marchionni. Dep. of Critical Care Medicine and Surgery, Section of Gerontology and Geriatrics, University, Florence, Italy
Journal: Journal of the American College of Cardiology (2001)
Research brief
Authors: Dara Mohammadi
Journal: The Lancet Infectious Diseases (2020)

US researchers have identified four compounds with in-vitro potency against severe respiratory syndrome coronavirus 2 (SARS-CoV-2). X-ray crystallography and 3D modelling of molecular docking showed that the compounds targeted the virus' main protease, Mpro, which is essential in host-cell entry and viral replication. The four compounds, identified after screening more than 50 proteases, included boceprevir (an FDA-approved hepatitis C drug) and GC-376, a veterinary drug under investigation for a feline coronavirus.
Severe Respiratory Illness Associated With a Novel Coronavirus — Saudi Arabia and Qatar, 2012
Journal: JAMA (2012)

CDC is working closely with the World Health Organization (WHO) and other partners to better understand the public health risk presented by a recently detected, novel coronavirus. This virus has been identified in two patients, both previously healthy adults who suffered severe respiratory illness. The first patient, a man aged 60 years from Saudi Arabia, was hospitalized in June 2012 and died; the second patient, a man aged 49 years from Qatar with onset of symptoms in September 2012 was transported to the United Kingdom for intensive care. He remains hospitalized on life support with both pulmonary and renal failure. Person-to-person or health-care-associated transmission has not been identified to date. Interim case definitions based on acute respiratory illness and travel history were issued by WHO on September 29 and include criteria for "patient under investigation," "probable case," and "confirmed case". This information is current as of October 4. Updates on the investigation and the WHO case definition are available at http://www.who.int/csr/don/en/index.html.